This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple international institutions conducted a prospective study to evaluate the natural history of disease progression in children with Charcot-Marie-Tooth (CMT) disease. Study participants were children 3–20 years old with CMT who were enrolled at 1 of 8 sites of the Inherited Neuropathies Consortium. Participating institutions were in the United States, Australia, and Europe. At enrollment (baseline), demographic information was collected on study children. In addition, CMT genotype was determined. At baseline and 2 years (±6 months) later, participants completed the CMT Pediatric Scale (CMTPedS), a validated 11-item performance-based measure assessing fine and gross motor function, strength, sensation, and balance. Possible CMTPedS scores range from 0–44, with higher scores indicative of more severe disease. Children with CMTPedS scores 0–14 are considered mildly affected, 15–29 …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.